Xiaoli Wei

机构：Sun Yat-sen University, Guizhou University, Anhui Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Guizhou Forestry Science Research Institute, 181st Hospital of Chinese People's Liberation Army, First Affiliated Hospital of Anhui Medical University, Sun Yat-sen University Cancer Center · ORCID：0000-0002-9284-3237

发表论文 71 篇 · 总被引 3572 次 · h-index 28

代表论文

• The prognostic value and molecular properties of tertiary lymphoid structures in oesophageal squamous cell carcinoma (2022 · Clinical and Translational Medicine · 被引 92)
• Current status and advances of immunotherapy in nasopharyngeal carcinoma (2022 · Therapeutic Advances in Medical Oncology · 被引 77)
• Evaluation of Safety of Treatment With Anti–Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors (2022 · JAMA Oncology · 被引 73)
• Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti–Programmed Cell Death 1 Immunotherapy (2022 · JAMA Network Open · 被引 68)
• Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma (2022 · Cell Reports Medicine · 被引 53)
• Myeloid beta-arrestin 2 depletion attenuates metabolic dysfunction-associated steatohepatitis via the metabolic reprogramming of macrophages (2024 · Cell Metabolism · 被引 38)